Genome sequencing reveals widespread COVID-19 infection in white-tailed deer

Houston Methodist’s SARS-CoV-2 genome sequencing team has partnered on a study led by Penn State that revealed 80% of white-tailed deer sampled across Iowa at the height of the 2020-2021 deer-hunting season tested positive for the SARS-CoV-2 virus. Analysis of the virus genome sequences revealed infections were likely the result of multiple human-to-deer transmission “spillover” events followed by deer-to-deer transmission from April 2020 through January 2021.

Expert Alert: 5 ways patients who are immunocompromised can protect themselves from COVID-19

As families prepare to gather later this month for Thanksgiving, it is important for patients who are immunocompromised to take extra steps to protect themselves from becoming infected with COVID-19. People who are immunocompromised have weakened immune systems, which means they have a higher risk of becoming severely ill from COVID-19.

Patients taking Rituximab Could Benefit from Third COVID-19 Vaccine Dose

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows patients using rituximab were able to produce antibodies against COVID-19 after receiving a third vaccine dose, even if there was no development of the antibody after the first two.

Rutgers Expert Available to Discuss Mixing and Matching of COVID-19 Vaccines, Booster Shots

Rutgers infectious disease expert Shobha Swaminathan is available to discuss the mixing and matching of COVID-19 vaccines and boosters as the Food and Drugs Administration authorized booster shots for both the Johnson & Johnson and Moderna vaccines. “There is mounting…

LLNL joins Human Vaccines Project to accelerate vaccine development and understanding of immune response

Lawrence Livermore National Laboratory has joined the international Human Vaccines Project, bringing Lab expertise and computing resources to the consortium to aid development of a universal coronavirus vaccine and improve understanding of immune response.

Study: No Serious COVID-19 Vaccine Side Effects in Breastfeeding Moms, Infants

Researchers found that breastfeeding mothers who received either the Pfizer-BioNTech or Moderna vaccination reported the same local or systemic symptoms as what has been previously reported in non-breastfeeding women, with no serious side effects in the breastfed infants.

FIELDING FOCUS | Covid-19 Conversation: Navigating Variants, Vaccines & Boosters

In this session, panelists Dr. Robert Kim-Farley (professor, departments of Epidemiology & Community Health Sciences) and Dr. Anne Rimoin (professor, Department of Epidemiology & director, Center for Global and Immigrant Health) will discuss the latest news on the pandemic in a conversation moderated by Dr. Ron Brookmeyer, dean of the UCLA Fielding School of Public Health & distinguished professor, Department of Biostatistics.

With Time and Without Masks, COVID-19 Vaccines Wane in Protection

A study measured effectiveness of COVID-19 mRNA vaccines among health workers, most notably during the emergence of delta virus variant and coincident with end of state’s mask mandate, finding protection waned over time, dropping sharply 6-8 months after full vaccination.

2VIDA! Tackles COVID Vaccine Hesitancy and Barriers in Latinx, Black Communities

UC San Diego is collaborating with San Ysidro Health on an NIH-funded outreach program to address COVID-19 vaccine hesitancy in Latinx and African American communities. The team runs pop-up vaccination sites across San Diego, and goes door-to-door to homes and local businesses to spread awareness.

What you need to know about the delta variant

For more than 40 years, UCI infectious disease researcher Michael Buchmeier has studied coronaviruses, and he’s one of the leading experts on SARS-CoV-2, the version of the virus causing the COVID-19 pandemic. As a more lethal mutation of the virus, called the delta variant, sparks another wave of cases, he offers his expertise about this threat.

Northwestern Kellogg Professor on America’s Failure To Deliver Sufficient Vaccines Worldwide and Why It Will Cost The U.S. Its Global Leadership

MEDIA ALERT – AUGUST 23, 2021  EVANSTON, IL — “While the U.S. is trying to incentivize Americans to get vaccinated, people in developing countries are protesting a lack of access. The U.S. needs to step up its global vaccine sharing, not…

Vaccine Hesitancy and Pregnancy: @UCSDHealth expert on why you should get the COVID-19 shot

With recent statewide vaccination mandates, members of the public may have questions or concerns about the safety and effectiveness of COVID-19 vaccination, especially in pregnant mothers. Cynthia Gyamfi-Bannerman, MD, professor and chair of Obstetrics, Gynecology and Reproductive Sciences at UC…

American Society of Anesthesiologists Strongly Encourages all Health Care Personnel to Get Vaccinated Against COVID-19

Amid the new surge of COVID-19 cases across the U.S., the American Society of Anesthesiologists (ASA), and eight professional societies associated with the specialty, are strongly encouraging the nation’s health care workers and all eligible Americans to get fully vaccinated with one of the COVID-19 vaccines. ASA and the associated societies remind the public that widespread vaccination is the most effective way to reduce illness and death.

AZ heroes study awarded $15M to continue, expand evaluation of COVID-19 immunity

A University of Arizona Health Sciences study of COVID-19 vaccine effectiveness and immunity among frontline workers has received a $15 million award from the U.S. Centers for Disease Control and Prevention (CDC) to continue the current research for another year…

CEPI and IVI collaborate on clinical research to expand access to COVID-19 vaccines in Africa

July 20, 2021; Oslo, Norway and Seoul, Republic of Korea: The Coalition for Epidemic Preparedness Innovations (CEPI) and the International Vaccine Institute (IVI) today announced a new programme of clinical research which aims to expand access to COVID-19 vaccines in…

New COVID-19 vaccine candidate provides effective option for low- to mid-income countries

A multidisciplinary team of researchers is the first to show combining yeast-expression technology and a novel adjuvant formulation to produce a COVID-19 vaccine candidate is effective against SARS-COV-2 and promises to be easy to produce at large scale and cost-effective, important aspects for vaccinating people worldwide, especially in low- to middle-income countries.